On 11/21/24, Avalo Therapeutics Inc (NASDAQ: AVTX) stock suffered a major decline of -11.5%, closing at $9.65. Moreover, this decline was accompanied by exceptionally high trading volume at 235% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -28.0% during the last week.
Current PriceTarget Research Rating
Avalo Therapeutics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Avalo Therapeutics has a poor Appreciation Score of 18 but a good Power Rating of 80, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment